Collaboration Opportunities with Ono Pharmaceutical in Non-clinical Stage or Late Stage of Drug Discovery Programs


12th May, 2022


09:00 - 10:00 UK Time


Zoom  (Pre-registration required)

Ono Pharmaceutical (Ono) is a medium-sized, R&D-oriented Japanese pharmaceutical company which first developed and launched Opdivo, a first in class PD-1 immune checkpoint inhibitor.

Ono focuses its research on the oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative drugs. Ono is looking for partnering opportunities with venture or biotech companies who have non-clinical stage or late stage of drug discovery program.

The Department for International Trade in Japan (DIT Japan) is delighted to announce a free online seminar together with Ono Pharmaceutical and One Nucleus to enable you to learn about Ono’s research priorities and collaboration opportunities.

Core interest areas are:

  • The Research Center of Oncology: As one of leading pioneers in immuno-oncology field, aiming to create “another Opdivo-class drugs” with unique targets and new technologies by incorporating latest science. Our areas of interest are immuno-oncology, next generation targeted therapy, and new modalities to overcome current treatment difficulties.
  • The Research Center of Immunology: Based on the long-year experience of immunology research leading to the successful development of Opdivo, the Center keeps research capabilities with a primary focus on biopharmaceutical development in immunology, working toward drug discovery in areas of cancer immunotherapy, autoimmune therapy and allergy.
  • The Research Center of Neurology: We have a strong and long-term commitment to R&D of neurology products. From our deep knowledge and R&D expertise, aiming to create innovative drugs for patients with neurodegenerative, psychiatric and pain disorders.  
  • The Research Center of Specialty: “Specialty” research at Ono is research activity in the development of clinically valuable products against diseases with high unmet medical needs such as autoimmune disease, fibrosis, regeneration and rare diseases. Drug discoveries with the understanding of pathogenesis will be a key for success in “Specialty” research.

The presentations will be followed by a Q&A session to help understand areas of further interest and collaboration. 

DIT Japan will assist 1:1 meeting requests from UK companies. 

Companies who wish to have an individual meeting with Ono Pharma, please send non-confidential slide deck to   DIT Japan will facilitate the meeting with Ono Pharma if they agree.